NCT06168968
Recruiting
N/A
Multidisciplinary Approach to Reduce Cardiovascular Health Disparities in the Baltimore RAcial Minority CommunitiEs (M-BRACE Trial)
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Acute Coronary Syndrome
- Sponsor
- LifeBridge Health
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- Differences in Platelet Fibrin Clot Formation (MA,mm)
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The goal of this observational study is to investigate the potential differences in thrombogenicity between black and white patients admitted with atherothrombotic events including acute coronary syndrome, multi-vessel coronary disease, and ischemic stroke.
Participants will engage in laboratory testing and health outcome assessments.
Investigators
Paul A. Gurbel
Director of Cardiovascular Research
LifeBridge Health
Eligibility Criteria
Inclusion Criteria
- •Patients ≥18 years of age admitted with ACS, AIS, or multi-vessel CAD
- •Competent mental condition to provide informed consent and able to participate in follow-ups
Exclusion Criteria
- •Pregnant women
- •Currently enrolled in an investigational drug or device trial
- •Undergoing treatment for neoplastic, autoimmune, or connective tissue disease
- •COVID-19 infection within 30 days of enrollment
- •Known history of hepatitis or HIV
- •Deemed unfit to participate according to the investigator
- •Known history of drug abuse
- •Known platelet count of \<100,000/mm3
- •Hematocrit \< 25%
Outcomes
Primary Outcomes
Differences in Platelet Fibrin Clot Formation (MA,mm)
Time Frame: Baseline
Differences in Platelet Fibrin Clot Formation (MA,mm) Between Black and White Patients
Differences in Speed of Clot Formation (R, min)
Time Frame: Baseline
Differences in Speed of Clot Formation (R, min) Between Black and White Patients
Secondary Outcomes
- Major Adverse Cardiovascular Events Post Index Hospitalization(3 and 12 months post index hospitalization)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
A Different Approach to Preventing ThrombosisVenous ThromboembolismPulmonary EmbolismNCT02774265University of Maryland, Baltimore329
Completed
Phase 2
Heart Disease on the MendCoronary Heart DiseaseStrokeHyperlipidemiaHypertensionNCT00127751Stanford University150
Enrolling by Invitation
Phase 2
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous ThromboembolismTrauma InjuryThromboembolismVenous ThromboembolismNCT05794165Bryan Cotton314
Unknown
N/A
The Effect of Empagliflozin on Glucose Metabolism, Weight, Blood Pressure and Cardiac Function (NT-proBNP) Should be InvestigatedDiabetes Mellitus, Type 2NCT03131232RWTH Aachen University46
Recruiting
N/A
Early Rheumatoid Arthritis COR InterventionRheumatoid ArthritisCardiovascular DiseasesNCT02246257MD, PhD, Annemarie Lyng Svensson300